<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Etiology and pathogenesis of relapsing polychondritis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Etiology and pathogenesis of relapsing polychondritis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Etiology and pathogenesis of relapsing polychondritis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marcela A Ferrada, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane Hoyt Buckner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapsing polychondritis (RPC) is a systemic inflammatory/degenerative disease with varying clinical manifestations that can include compromise of the structural and functional integrity of cartilage; organs of special sense; and the cardiovascular, renal, and nervous systems  (
         <a class="graphic graphic_table graphicRef76071" href="/z/d/graphic/76071.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5606.html" rel="external">
          "Clinical manifestations of relapsing polychondritis"
         </a>
         .)
        </p>
        <p>
         This topic will review our current understanding of the etiology and pathogenesis of RPC. The pathologic changes in this disorder are described elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5621.html" rel="external">
          "Pathology of relapsing polychondritis"
         </a>
         .)
        </p>
        <p>
         The approach to diagnosis and treatment of RPC are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5609.html" rel="external">
          "Diagnostic evaluation of relapsing polychondritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5587.html" rel="external">
          "Treatment of relapsing polychondritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The etiology of relapsing polychondritis (RPC) is unknown. Although few clues are evident, there appears to be a genetic susceptibility, an overlap with other disorders associated with immunologic abnormalities, and the potential for multiple inciting events including chemical insults, direct trauma, and infections. This hypothesis is supported by a series of observations that imply that RPC is not a primary disease, but a syndrome associated with multiple precipitating factors that appear in a genetically susceptible subject. (See
         <a class="local">
          'Genetic susceptibility'
         </a>
         below and
         <a class="local">
          'Association with other immunologic and bone marrow diseases'
         </a>
         below and
         <a class="local">
          'Induction by triggers'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Genetic susceptibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         No association of RPC with human leukocyte antigen (HLA) class I (HLA-A and HLA-B) antigens has been identified [
         <a href="#rid1">
          1
         </a>
         ]. However, an association has been described between RPC and HLA class II, specifically with HLA-DR4 [
         <a href="#rid2">
          2
         </a>
         ]. Genetic analysis of the frequency of HLA class II histocompatibility antigens was performed in 60 White Central European patients with RPC [
         <a href="#rid2">
          2
         </a>
         ]; the frequency of HLA-DR4 was 56 percent compared with 26 percent in a healthy control group. Genotyping showed no preferential association of specific DR4 subtype alleles, in contrast to the clear association of rheumatoid arthritis (RA) with DRB1*0401 and DRB1*0404 [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Subsequent evidence from a Japanese population could not confirm an association with HLA-DR4. However, these investigators identified three HLA class II alleles in linkage disequilibrium with each other and associated with RPC. Two of the alleles are seen predominately in Eastern Asian populations and not thought to be generalizable. HLA-DQB1*05:02, the third allele, is also present in European populations and could be a focus of additional genotyping studies. In the Eastern Asian population, the three alleles did not influence the clinical features of the disease [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The RA-associated alleles have in common a region of highly similar sequence, designated the shared epitope. Thus, although RPC and RA may share clinical and immunologic features and, at times, may coexist, the contribution of HLA-DRB1*04 alleles to disease may differ between these two disorders. (See
         <a class="medical medical_review" href="/z/d/html/7487.html" rel="external">
          "HLA and other susceptibility genes in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
         Another observation made in one of these studies was a negative association between HLA-DR6 positivity and clinical features of RPC, including extent of organ involvement and specific organ manifestations (such as general symptoms and nasal chondritis) [
         <a href="#rid2">
          2
         </a>
         ]. HLA-DR6-positive patients also had a higher median age at disease onset compared with HLA-DR6-negative patients. The importance of this relationship is unclear and remains speculative.
        </p>
        <p>
         A role for HLA class II DQ alleles was suggested by one preliminary report of a study that evaluated HLA class II allelic distribution among 64 unrelated White RPC patients compared with 507 unrelated healthy controls [
         <a href="#rid5">
          5
         </a>
         ]. The following allele frequencies were significantly increased in RPC: DQB1*0601 (4.7 versus 0.9 percent), DQA1*0103 (15.6 versus 7.9 percent) and DQA1*0301 (22.7 versus 12.9 percent). In addition, 59 percent of patients expressed the DQA1*0103 or 0301 allele compared with 38 percent of controls. This is further supported by the report that double transgenic mice which express both DQA1*0301/DQB1*0302 and DQA1*0103/DQB1*0601 class II molecules develop severe experimental RPC following immunization with type II collagen. (See
         <a class="local">
          'Genetic predisposition in experimental models'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Association with other immunologic and bone marrow diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a frequent association of RPC with a diverse array of connective tissue, endocrine, and inflammatory bowel diseases in which immunologic mechanisms are believed to have a prominent role in pathogenesis. These include systemic necrotizing forms of vasculitis, Graves' disease, and ulcerative colitis  (
         <a class="graphic graphic_table graphicRef81401" href="/z/d/graphic/81401.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5606.html" rel="external">
          "Clinical manifestations of relapsing polychondritis"
         </a>
         .)
        </p>
        <p>
         Since the mid-1990s, there has been recognition of a particular subgroup of patients with an overlap of RPC and myelodysplastic syndrome (MDS) [
         <a href="#rid6">
          6-8
         </a>
         ]. These patients were mostly described as older males, with high mortality, an absence of airway chondritis, and a diagnosis of MDS [
         <a href="#rid9">
          9
         </a>
         ]. Subsequently, the description of a newly defined syndrome called VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, found that somatic mutations in the
         <em>
          UBA1
         </em>
         gene caused a disease characterized by an overlap of inflammatory and hematologic features including MDS. In the first description of VEXAS, a high proportion of patients carried a clinical diagnosis of RPC, and patients with VEXAS were older and males, for the most part, due to the mutations being X-linked [
         <a href="#rid10">
          10
         </a>
         ]. Thus, it is very likely that the cause of the previously described subgroup of RPC overlapping with MDS was due to VEXAS syndrome. Another study has found that 7.6 percent of patients with RPC in a prospective observational cohort of RPC patients referred to the US National Institutes of Health (NIH) had VEXAS syndrome [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122508.html" rel="external">
          "Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity", section on 'Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Autoimmune/inflammatory conditions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11225833">
         <span class="h2">
          Induction by triggers
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxins
         </strong>
         – A disease simulating RPC (auricular/nasal cartilage inflammation, scleritis, audiovestibular, and peripheral and axial joint involvement) appeared within 24 hours of an intravenous injection of a preheated multiple substance "cocktail" [
         <a href="#rid12">
          12
         </a>
         ]. This cocktail included hydrochloric acid, carburetor fluid, the waxy internal matrix of a mentholated nasal inhaler, and tap water. This bizarre event is reminiscent of early experimental studies showing that intravenously injected crude papain could induce collapse of the normally rigid ears of young rabbits within four hours of administration, followed in some animals by respiratory distress caused by tracheal and bronchial collapse [
         <a href="#rid13">
          13
         </a>
         ]. There was widespread but reversible diffuse loss of connective tissue metachromasia consistent with proteoglycan depletion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trauma
         </strong>
         – Direct trauma to cartilaginous structures has also been described as a trigger of RPC. The mechanisms associated with this process have been proposed to be due to trauma causing exposure of cartilage matrix protein antigens. These antigens generate an autoimmune response by producing autoantibodies and autoreactive T lymphocytes towards cartilaginous structures that will then generate chondritis in other anatomic locations [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – Infections have been recognized as a trigger of autoimmunity in other conditions by generating an innate immune response mediated by nucleotide-binding oligomerization domain-like receptor (NLR) and toll-like receptor (TLR) signaling [
         <a href="#rid15">
          15
         </a>
         ]. A few cases of RPC associated with hepatitis C have been reported, suggesting a possible role of infections as a trigger of RPC [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the inciting cause may vary, increasing evidence derived from human and experimental animal studies has clearly implicated genetically preconditioned phlogistic and immunologic mechanisms that disturb connective tissue structure and cell function. In addition to the association with human leukocyte antigen (HLA) DR4, the following observations are consistent with this hypothesis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of autoimmunity, both antibody and cell-mediated, to extracellular matrix components of cartilage such as types II, IX and XI collagen, matrilin-1, and proteoglycan constituent fractions [
         <a href="#rid18">
          18-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some observations support the contribution of a cell-mediated immune reaction to type II collagen [
         <a href="#rid21">
          21
         </a>
         ]. As an example, T cell clones isolated from a DRB1*0101/0401 heterozygous patient with relapsing polychondritis (RPC) showed specificity to a peptide derived from type II collagen that is an immunodominant epitope in a transgenic mouse model with features of RPC. Of further interest are differences found in the epitope specificity for type II collagen antibody identified in patients with rheumatoid arthritis versus RPC. Response in the rheumatoid patients was directed to an evolutionary conserved type II collagen domain that is also targeted by pathogenic autoimmune responses in murine models of arthritis but not RPC [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prominence of HLA-DR-positive antigen-presenting cells and CD4-positive T lymphocytes at lesional sites [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cartilage destruction may also be mediated by induction of apoptosis in chondrocytes. Chondrocyte expression of matrix metalloproteinase (MMP)–3 and cathepsin-K is strongly associated with this finding [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The genetically governed experimental induction of features of RPC following immunization of experimental animals with connective tissue antigens. (See
         <a class="local">
          'Genetic predisposition in experimental models'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Selective decreases in the number and function of natural killer regulatory T cells (NKT cells), a novel lymphocyte lineage distinct from conventional T, B, or NK cells which are believed to be involved in control of expression of autoimmune disease by modulating the balance of cytokine expression [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Findings such as these have led to the generation of a unifying hypothesis which takes into account genetic predisposition, the immunogenicity of cartilage, and specific immunologic pathways important in mediating the disease process  (
         <a class="graphic graphic_algorithm graphicRef70792" href="/z/d/graphic/70792.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Immunogenicity of cartilage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cartilage proteoglycans, collagen types, elastin, and the chondrocyte cell membrane express multiple epitopes capable of eliciting an immune response [
         <a href="#rid26">
          26-28
         </a>
         ]. These epitopes are largely masked in the native state because of their conformational structure.
        </p>
        <p>
         Fundamental to an understanding of the immunopathologic significance of such connective tissue constituents in RPC is an awareness of their tissue distribution, since the lesions in RPC usually involve the trachea, nose, and outer ears, and the sharing of antigenicity.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although type II collagen is transiently present in many tissues during embryogenesis, it is subsequently expressed at only two sites: the fibrillar scaffolding of cartilage matrix, and the vitreous of the eye [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type IX collagen, a fibril-associated form with interrupted triple helices, has proteoglycan properties. It is a molecular coupler that organizes and anchors type II collagen fibrils in a defined three-dimensional pattern within connective tissue matrix.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type XI collagen, which regulates fibril size, is uniformly distributed in cartilage and dominantly concentrated in pericellular regions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although matrilin-1 is a matrix protein unique to fetal epiphyseal cartilage, it is only expressed in adults in auricular, nasal, tracheal, and costochondral cartilages [
         <a href="#rid30">
          30,31
         </a>
         ]. In animal models, immunization to matrilin-1 can induce an RPC-like syndrome. (See
         <a class="local">
          'Matrilin-1'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Proteoglycan-shared epitopes are diversely distributed and can be found in a variety of tissues including connective tissue of aortic media and intima, the anterior uveal tract, heart valves, the endoneurium and perineurium of the optic nerves, the tracheal submucosal basement membrane, endothelial cells, glomerular and tubular basement membranes, myocardial sarcolemma, and synoviocytes [
         <a href="#rid26">
          26-29,32
         </a>
         ].
        </p>
        <p>
         Of speculative interest is the antigenic crossreactivity between cartilage proteoglycans, streptococcal peptidoglycans, and the purified protein derivative of
         <em>
          Mycobacterium tuberculosis
         </em>
         [
         <a href="#rid33">
          33
         </a>
         ]. In this context, a monoclonal antibody derived from peripheral blood B cells of a patient with RPC reacted with a purified cytoskeletal antigen (desmin), type II collagen, and proteoglycans [
         <a href="#rid34">
          34
         </a>
         ]. Crossreactivity of this antibody to heat shock protein 60 obtained from
         <em>
          M. tuberculosis
         </em>
         was also shown. The possibility that an exogenous antigen induces an antibody capable of cross-reacting with autoantigens and thus contributing to the pathogenic process cannot be dismissed.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Genetic predisposition in experimental models
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rodents and primates immunized with native type II or XI cartilage collagen may develop a major histocompatibility complex (MHC)-restricted destructive arthropathy which correlates both with the expression of antibodies specific for conformational determinants of collagen and cell-mediated immune responses which lack conformational or collagen type specificity [
         <a href="#rid35">
          35,36
         </a>
         ]. It is unclear as to whether T cells alone can induce arthritis, although they are likely to have a major role in sustaining the process. An auricular chondritis may develop later in the postimmunization period, independent of the expression of arthritis [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         These responses appear to be under multiple gene control which is, in part, linked to the Ir region of the MHC [
         <a href="#rid39">
          39,40
         </a>
         ]. This region is thought to be responsible for regulation of the expression, severity, and rate of progression of disease. An imbalance of T-helper cell subsets may play an important role in the development of cartilage destruction in this model [
         <a href="#rid41">
          41
         </a>
         ]. However, there are no ocular, laryngotracheobronchial, or cardiovascular lesions in collagen-induced arthritis, as there are in human RPC.
        </p>
        <p>
         The role of DQ class II molecules in the antigenic presentation of type II collagen and subsequent initiation of collagen-induced arthritis has been studied using transgenic mice lacking endogenous HLA class II molecular expression [
         <a href="#rid42">
          42
         </a>
         ]. These HLA molecules, which are expressed on the cell surface, can positively select CD4+ T cells expressing various V beta T cell receptors. Transgenic mice that express DQ8 develop severe arthritis in response to collagen immunization; by comparison, DQ6 mice are unresponsive. Double transgenic mice expressing both DQ6 and DQ8 develop severe RPC following type II collagen immunization, exhibiting both polyarthritis and auricular chondritis. Older mice bearing both DQ6 and DQ8 develop chondritis spontaneously (in the absence of collagen immunization or adjuvant administration) [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Expression of DQ8 in mice with a nonobese diabetic (NOD) genotype and lacking endogenous class II molecules is also associated with a susceptibility to type II collagen-immunization-induced chondritis [
         <a href="#rid44">
          44
         </a>
         ]. In this transgenic strain, immunization with type II collagen produces auricular cartilage inflammation in a larger proportion of animals and also produces an antibody response to both type II and type IX collagen. Immunization of this mouse strain with type IX collagen frequently leads to chondritis.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Matrilin-1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other models have used cartilage matrix protein (matrilin-1) as the immunogen in an attempt to replicate the tissue distribution of lesions in RPC [
         <a href="#rid45">
          45,46
         </a>
         ]. Matrilin-1 is primarily expressed in skeletal growth cartilage during development but is limited to the nasal septum, trachea, auricular, and xiphisternal cartilage in adulthood [
         <a href="#rid30">
          30,31
         </a>
         ]. Immunization of rats with this protein produces severe inspiratory stridor due to tracheal involvement, nasal swelling, and/or epistaxis [
         <a href="#rid45">
          45
         </a>
         ]. Female rats were more susceptible than males. All strains mount a strong IgG anti-matrilin-1 response, but only some strains develop disease. Using congenic mouse strains, the likelihood of developing disease appears to be governed by both MHC and non-MHC genes, and is dependent upon alpha beta T cells [
         <a href="#rid47">
          47
         </a>
         ]. Mice devoid of interleukin (IL)-10 through gene deletion develop a significantly more severe disease with earlier onset.
        </p>
        <p>
         Further studies using the matrilin-1 model have shown both an antibody- and complement-dependent basis for RPC development. Neither specific antibody nor disease could be induced in matrilin-1 immunized mice deficient of B cells [
         <a href="#rid48">
          48
         </a>
         ]. B-cell deficient mice injected with matrilin-1 specific antibody developed erosive respiratory tract chondritis. Respiratory distress occurred significantly less in matrilin-1 immunized mice congenic at complement factor 5, indicating the potential importance of, although not an absolute requirement for, functional C5.
        </p>
        <p>
         The applicability of these findings to humans is uncertain. Matrilin-1 fragments have been identified in the serum of a patient with RPC during active inflammation [
         <a href="#rid46">
          46
         </a>
         ], and both humoral and cell-mediated immune responses were documented in other patients [
         <a href="#rid46">
          46,49
         </a>
         ]. Anti-matrilin antibodies are present in a minority of patients with RPC. This was illustrated by a study of the sera of 97 patients obtained at a single time point in their disease course; 13 of 97 had IgG and/or IgM anti-matrilin-1 antibody; positive responses correlated with respiratory symptoms in 69 percent of the cases [
         <a href="#rid50">
          50
         </a>
         ]. However, 40 percent of patients having clinical evidence of laryngotracheal involvement did not have an anti-matrilin-1 antibody response.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Immunologic pathways mediating cartilage degradation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The immune response and subsequent release of cytokines may be responsible for cartilage destruction in RPC. Immune complexes, formed in situ and/or localized by affinity to polyanionic proteoglycans, bind to the surface of cartilage. Attempted removal by scavenger cells facilitates release of matrix degrading metalloproteinases, oxygen metabolites and/or cytokines [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Cytokines such as IL-1 and tumor necrosis factor (TNF) induce chondrocyte production of matrix-degrading metalloproteinases, plasminogen activator and prostanoids [
         <a href="#rid51">
          51-53
         </a>
         ]. They may also reversibly downregulate chondrocyte collagen and/or proteoglycan synthesis [
         <a href="#rid54">
          54-57
         </a>
         ].
        </p>
        <p>
         A major role for cell-mediated immune responses in the pathophysiology of RPC is suggested by serum cytokine profile studies [
         <a href="#rid58">
          58
         </a>
         ]. A set of circulating cytokines levels were contrasted between patients with active RPC, patients with rheumatoid arthritis, and healthy control subjects. Mean serum levels of monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1 beta (MIP-1 beta), and IL-8 were significantly higher in patients with RPC than controls. The profile in rheumatoid arthritis differed, showing a more generalized pattern of upregulation of multiple cytokines rather than the more discrete elevations observed in RPC. Each of the three cytokines increased in RPC is a proinflammatory chemokine; MCP-1 and MIP-1 beta function to recruit and activate circulating monocyte/macrophages. IL-8 is produced by activated monocyte/macrophages, acting in part to attract neutrophils. Chondrocytes constitutively express and store these cytokines and their receptors are found on activated T cells.
        </p>
        <p>
         Cartilage contains a constitutive and inducible growth factor/cytokine metabolic regulatory network, which may function in an autocrine/paracrine manner to modulate normal cartilage growth and metabolism. It may also serve a pathophysiologic role, contributing to altered chondrocyte metabolism and ineffectual tissue repair [
         <a href="#rid59">
          59
         </a>
         ]. As an example, basic fibroblast growth factor, an integral part of this network, upregulates IL-1 and TNF receptors. Insulin-like growth factor-1 activity, which is essential for optimal chondrocyte anabolic function, is inhibited by these cytokines [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Unifying hypothesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A hypothetical scheme for the pathogenesis of RPC begins with insult-induced exposure of connective tissue or cell membrane epitopes, leading to an inflammatory and genetically conditioned immune response  (
         <a class="graphic graphic_algorithm graphicRef70792" href="/z/d/graphic/70792.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         Cartilage may be viewed as an immunologically "privileged" tissue because of both the conformational structure of its basic connective tissue constituents and its avascular and alymphatic milieu. Privileged refers to failure of development of immunologic tolerance to self-components.
        </p>
        <p>
         The integrity of cartilage in RPC can speculatively be compromised by multiple inciting factors including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An insult, irrespective of cause, to nutrient vasculature at sites contiguous to cartilage, with an ensuing inflammatory cell exudate being responsible for tissue injury
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A direct traumatic, toxic, infectious, or chemical insult
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systemic or localized process which directly or indirectly perturbs chondrocyte metabolism by modulating exposure to essential hormones and growth factors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An infectious agent having a cytotropic propensity for chondrocytes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antigenic mimicry between an infectious agent and a given connective tissue antigen as noted above
        </p>
        <p>
        </p>
        <p>
         The ensuing matrix compromise may lead to release of or in situ exposure to native or modified connective tissue antigens. Genetically conditioned host sensitization would facilitate generation of both humoral and cell-mediated immune responses. Pathologic consequences, in part representing in situ complex formation, may be widespread because of epitope sharing with matrix constituents. Alternatively, cartilage and other connective tissue sites may serve as innocent bystanders, reflecting an affinity-associated adsorption of preformed complexes.
        </p>
        <p>
         The ensuing inflammatory response would perpetuate enzymatic and oxygen metabolite-mediated connective tissue degradation. Cytokines released into the milieu can further contribute to the pathologic process by inducing chondrocyte and connective tissue fibroblast proteinase release, perturbing matrix repair, and inciting constitutional symptoms and an acute phase response.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – The etiology of relapsing polychondritis (RPC) is unknown, and multiple inciting events have been postulated. Genetic susceptibility is suggested by the association between RPC and human leukocyte antigen (HLA) DR4 or other HLA class II alleles. (See
         <a class="local">
          'Genetic susceptibility'
         </a>
         above and
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Associated disorders
         </strong>
         – There is a frequent association of RPC with a diverse array of immune-mediated connective tissue, endocrine, and inflammatory bowel diseases, including systemic necrotizing forms of vasculitis, Graves' disease, and ulcerative colitis. A high proportion of patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome meet a clinical diagnosis of RPC. (See
         <a class="local">
          'Association with other immunologic and bone marrow diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of autoimmunity and immune cell dysfunction in pathogenesis
         </strong>
         – There is evidence of autoimmunity, both antibody- and cell-mediated, to extracellular matrix components of cartilage, including types II, IX and XI collagen; matrilin-1; and proteoglycan constituent fractions. (See
         <a class="local">
          'Immunogenicity of cartilage'
         </a>
         above and
         <a class="local">
          'Matrilin-1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Findings include the prominence of HLA-DR-positive antigen-presenting cells and CD4-positive T lymphocytes at lesional sites and selective decreases in the number and function of natural killer regulatory T cells (NKT cells). (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Experimental induction of features of RPC following immunization of experimental animals with connective tissue antigens is genetically regulated. (See
         <a class="local">
          'Genetic predisposition in experimental models'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unifying hypothesis for mechanisms of cartilage injury
         </strong>
         – RPC is hypothesized to result from exposure of modified or immunologically privileged connective tissue or cell membrane epitopes by an unknown inciting event, leading to an inflammatory and genetically conditioned immune response. The response to injury may perpetuate enzymatic and oxygen metabolite-mediated connective tissue degradation and subsequent release of cytokines, which may be responsible for cartilage destruction. (See
         <a class="local">
          'Immunologic pathways mediating cartilage degradation'
         </a>
         above and
         <a class="local">
          'Unifying hypothesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H959924300">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Clement J Michet, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Luthra HS, McKenna CH, Terasaki PI. Lack of association of HLA-A and B locus antigens with relapsing polychondritis. Tissue Antigens 1981; 17:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeuner M, Straub RH, Rauh G, et al. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol 1997; 24:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao XJ, Olsen NJ, Pincus T, Stastny P. HLA-DR alleles with naturally occurring amino acid substitutions and risk for development of rheumatoid arthritis. Arthritis Rheum 1990; 33:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terao C, Yoshifuji H, Yamano Y, et al. Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases. Rheumatology (Oxford) 2016; 55:1686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hue-Lemoine S, Caillat-Zucman S, Amoura S, et al. HLA-DQA1 and DQB1 alleles are associated with susceptibility to relapsing polychondritis: From transgenic mice to humans. Arthritis Rheum 1999; 42:S261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piette JC, Papo T, Chavanon P, et al. Myelodysplasia and relapsing polychondritis. J Rheumatol 1995; 22:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbar M, Brouillard M, Wattel E, et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia 1995; 9:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francès C, el Rassi R, Laporte JL, et al. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine (Baltimore) 2001; 80:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dion J, Costedoat-Chalumeau N, Sène D, et al. Relapsing Polychondritis Can Be Characterized by Three Different Clinical Phenotypes: Analysis of a Recent Series of 142 Patients. Arthritis Rheumatol 2016; 68:2992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck DB, Ferrada MA, Sikora KA, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2020; 383:2628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrada MA, Sikora KA, Luo Y, et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol 2021; 73:1886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger R. Polychondritis resulting from intravenous substance abuse. Am J Med 1988; 85:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCLUSKEY RT, THOMAS L. The removal of cartilage matrix, in vivo, by papain; identification of crystalline papain protease as the cause of the phenomenon. J Exp Med 1958; 108:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cañas CA, Bonilla Abadía F. Local cartilage trauma as a pathogenic factor in autoimmunity (one hypothesis based on patients with relapsing polychondritis triggered by cartilage trauma). Autoimmune Dis 2012; 2012:453698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang CL, Brinckmann J, Rui HF, et al. Autoantibodies to cartilage collagens in relapsing polychondritis. Arch Dermatol Res 1993; 285:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemmati I, Yoshida E, Shojania K. Relapsing polychondritis associated with hepatitis C virus infection. Clin Rheumatol 2012; 31:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrera I, Concha R, Molina EG, et al. Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia. Semin Arthritis Rheum 2004; 33:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foidart JM, Abe S, Martin GR, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978; 299:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebringer R, Rook G, Swana GT, et al. Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases. Ann Rheum Dis 1981; 40:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman JH, Dennis MV. Immunopathologic studies in relapsing polychondritis. J Clin Invest 1973; 52:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckner JH, Van Landeghen M, Kwok WW, Tsarknaridis L. Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis. Arthritis Rheum 2002; 46:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burkhardt H, Koller T, Engström A, et al. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum 2002; 46:2339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riccieri V, Spadaro A, Taccari E, Zoppini A. A case of relapsing polychondritis: pathogenetic considerations. Clin Exp Rheumatol 1988; 6:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouchi N, Uzuki M, Kamataki A, et al. Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in relapsing polychondritis. J Rheumatol 2011; 38:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takagi D, Iwabuchi K, Iwabuchi C, et al. Immunoregulatory defects of V alpha 24V+ beta 11+ NKT cells in development of Wegener's granulomatosis and relapsing polychondritis. Clin Exp Immunol 2004; 136:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman JH, Carpenter BA. Immunobiology of cartilage. Semin Arthritis Rheum 1975; 5:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker JR, Caterson B, Christner JE. Immunological characterization of cartilage proteoglycans. Methods Enzymol 1982; 83:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glant T, Mikecz K. Antigenic profiles of human, bovine and canine articular chondrocytes. Cell Tissue Res 1986; 244:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart JM, Cremer MA, Dixit SN, et al. Collagen-induced arthritis in rats. Comparison of vitreous and cartilage-derived collagens. Arthritis Rheum 1979; 22:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mörgelin M, Paulsson M, Heinegård D, et al. Evidence of a defined spatial arrangement of hyaluronate in the central filament of cartilage proteoglycan aggregates. Biochem J 1995; 307 ( Pt 2):595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu JJ, Eyre DR. Matrilin-3 forms disulfide-linked oligomers with matrilin-1 in bovine epiphyseal cartilage. J Biol Chem 1998; 273:17433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poole AR, Pidoux I, Reiner A, et al. Mammalian eyes and associated tissues contain molecules that are immunologically related to cartilage proteoglycan and link protein. J Cell Biol 1982; 93:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Eden W, Holoshitz J, Nevo Z, et al. Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci U S A 1985; 82:5117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menge T, Rzepka R, Melchers I. Monoclonal autoantibodies from patients with autoimmune diseases: specificity, affinity and crossreactivity of MAbs binding to cytoskeletal and nucleolar epitopes, cartilage antigens and mycobacterial heat-shock protein 60. Immunobiology 2002; 205:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977; 146:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo TJ, Kim SY, Stuart JM, et al. Induction of arthritis in monkeys by immunization with type II collagen. J Exp Med 1988; 168:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremer MA, Pitcock JA, Stuart JM, et al. Auricular chondritis in rats. An experimental model of relapsing polychondritis induced with type II collagen. J Exp Med 1981; 154:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCune WJ, Schiller AL, Dynesius-Trentham RA, Trentham DE. Type II collagen-induced auricular chondritis. Arthritis Rheum 1982; 25:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths MM, Eichwald EJ, Martin JH, et al. Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum 1981; 24:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981; 154:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley DS, Das P, Griffiths MM, et al. HLA-DQ6/8 double transgenic mice develop auricular chondritis following type II collagen immunization: a model for human relapsing polychondritis. J Immunol 1998; 161:5046.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamoureux JL, Buckner JH, David CS, Bradley DS. Mice expressing HLA-DQ6alpha8beta transgenes develop polychondritis spontaneously. Arthritis Res Ther 2006; 8:R134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taneja V, Griffiths M, Behrens M, et al. Auricular chondritis in NOD.DQ8.Abetao (Ag7-/-) transgenic mice resembles human relapsing polychondritis. J Clin Invest 2003; 112:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansson AS, Heinegård D, Holmdahl R. A new animal model for relapsing polychondritis, induced by cartilage matrix protein (matrilin-1). J Clin Invest 1999; 104:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckner JH, Wu JJ, Reife RA, et al. Autoreactivity against matrilin-1 in a patient with relapsing polychondritis. Arthritis Rheum 2000; 43:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansson AS, Johansson AC, Holmdahl R. Critical role of the major histocompatibility complex and IL-10 in matrilin-1-induced relapsing polychondritis in mice. Arthritis Res Ther 2004; 6:R484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansson AS, Johannesson M, Svensson L, et al. Relapsing polychondritis, induced in mice with matrilin 1, is an antibody- and complement-dependent disease. Am J Pathol 2004; 164:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxne T, Heinegård D. Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis. Arthritis Rheum 1995; 38:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansson AS, Heinegård D, Piette JC, et al. The occurrence of autoantibodies to matrilin 1 reflects a tissue-specific response to cartilage of the respiratory tract in patients with relapsing polychondritis. Arthritis Rheum 2001; 44:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman JH, Greenblatt D, Khosla RC, Appel AM. Cytokine modulation of chondrocyte proteinase release. Arthritis Rheum 1984; 27:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dingle JT, Page Thomas DP, King B, Bard DR. In vivo studies of articular tissue damage mediated by catabolin/interleukin 1. Ann Rheum Dis 1987; 46:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman JH, Nutman TB, Nozoe M, et al. Lymphokine-mediated suppression of chondrocyte glycosaminoglycan and protein synthesis. Arthritis Rheum 1981; 24:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman JH, Khosla RC, Mowery CS, Appel AM. Modulation of chondrocyte synthesis by lymphokine-rich conditioned media. Arthritis Rheum 1982; 25:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldring MB, Sandell LJ, Stephenson ML, Krane SM. Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes. J Biol Chem 1986; 261:9049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldring MB, Birkhead J, Sandell LJ, et al. Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. J Clin Invest 1988; 82:2026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stabler T, Piette JC, Chevalier X, et al. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum 2004; 50:3663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herman JH, O'Connor MP, Lieberman MA. Perturbation of a Cartilage Autocrine/Paracrine Basic Fibroblast Growth Factor Metabolic Regulatory Network by Osteoarthritic Synovial Tissue. Am J Ther 1996; 3:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. Lymphokine Cytokine Res 1993; 12:219.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5604 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6949338" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lack of association of HLA-A and B locus antigens with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9002018" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2369430" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : HLA-DR alleles with naturally occurring amino acid substitutions and risk for development of rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27241705" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Genotyping of relapsing polychondritis identified novel susceptibility HLA alleles and distinct genetic characteristics from other rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : HLA-DQA1 and DQB1 alleles are associated with susceptibility to relapsing polychondritis: From transgenic mice to humans
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7674259" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Myelodysplasia and relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723411" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Association of myelodysplastic syndrome and relapsing polychondritis: further evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11388093" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27331771" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Relapsing Polychondritis Can Be Characterized by Three Different Clinical Phenotypes: Analysis of a Recent Series of 142 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33108101" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33779074" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3414736" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Polychondritis resulting from intravenous substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13575673" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The removal of cartilage matrix, in vivo, by papain; identification of crystalline papain protease as the cause of the phenomenon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22110903" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Local cartilage trauma as a pathogenic factor in autoimmunity (one hypothesis based on patients with relapsing polychondritis triggered by cartilage trauma).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8379684" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Autoantibodies to cartilage collagens in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22052586" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Relapsing polychondritis associated with hepatitis C virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15190524" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/714080" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Antibodies to type II collagen in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7030234" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Autoantibodies to cartilage and type II collagen in relapsing polychondritis and other rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4265382" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Immunopathologic studies in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11817597" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12355481" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3396253" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A case of relapsing polychondritis: pathogenetic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239745" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cartilage destruction is partly induced by the internal proteolytic enzymes and apoptotic phenomenon of chondrocytes in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15147365" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Immunoregulatory defects of V alpha 24V+ beta 11+ NKT cells in development of Wegener's granulomatosis and relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1098150" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Immunobiology of cartilage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6808300" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Immunological characterization of cartilage proteoglycans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3521881" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Antigenic profiles of human, bovine and canine articular chondrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/426881" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Collagen-induced arthritis in rats. Comparison of vitreous and cartilage-derived collagens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7733901" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evidence of a defined spatial arrangement of hyaluronate in the central filament of cartilage proteoglycan aggregates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9651330" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Matrilin-3 forms disulfide-linked oligomers with matrilin-1 in bovine epiphyseal cartilage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7119004" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mammalian eyes and associated tissues contain molecules that are immunologically related to cartilage proteoglycan and link protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3927297" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11999339" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Monoclonal autoantibodies from patients with autoimmune diseases: specificity, affinity and crossreactivity of MAbs binding to cytoskeletal and nucleolar epitopes, cartilage antigens and mycobacterial heat-shock protein 60.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/894190" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Autoimmunity to type II collagen an experimental model of arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3411292" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Induction of arthritis in monkeys by immunization with type II collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7021752" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Auricular chondritis in rats. An experimental model of relapsing polychondritis induced with type II collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7039630" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Type II collagen-induced auricular chondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6972765" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6792316" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8766554" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9794442" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : HLA-DQ6/8 double transgenic mice develop auricular chondritis following type II collagen immunization: a model for human relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16872515" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Mice expressing HLA-DQ6alpha8beta transgenes develop polychondritis spontaneously.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14679179" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Auricular chondritis in NOD.DQ8.Abetao (Ag7-/-) transgenic mice resembles human relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10487773" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A new animal model for relapsing polychondritis, induced by cartilage matrix protein (matrilin-1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10765942" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Autoreactivity against matrilin-1 in a patient with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15380048" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Critical role of the major histocompatibility complex and IL-10 in matrilin-1-induced relapsing polychondritis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14982849" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Relapsing polychondritis, induced in mice with matrilin 1, is an antibody- and complement-dependent disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7848324" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11665983" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The occurrence of autoantibodies to matrilin 1 reflects a tissue-specific response to cartilage of the respiratory tract in patients with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6318778" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cytokine modulation of chondrocyte proteinase release.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3736671" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3499123" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : In vivo studies of articular tissue damage mediated by catabolin/interleukin 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6972767" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Lymphokine-mediated suppression of chondrocyte glycosaminoglycan and protein synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7092965" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Modulation of chondrocyte synthesis by lymphokine-rich conditioned media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3087985" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Immune interferon suppresses levels of procollagen mRNA and type II collagen synthesis in cultured human articular and costal chondrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3264290" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15529362" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11856997" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Perturbation of a Cartilage Autocrine/Paracrine Basic Fibroblast Growth Factor Metabolic Regulatory Network by Osteoarthritic Synovial Tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8218594" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
